Drug Type Monoclonal antibody |
Synonyms anti-CD19 MAb XmAb5574, anti-CD19 MoAb XmAb5574, Tafasitamab + [8] |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Antibody-dependent cellular phagocytosis (ADCP) effects |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (31 Jul 2020), |
RegulationBreakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (AU), Conditional marketing approval (EU), Conditional marketing approval (US) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diffuse Large B-Cell Lymphoma | US | 31 Jul 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse large B-cell lymphoma recurrent | NDA/BLA | CN | 21 Jun 2024 | |
Diffuse large B-cell lymphoma recurrent | NDA/BLA | CN | 21 Jun 2024 | |
Diffuse large B-cell lymphoma refractory | NDA/BLA | CN | 21 Jun 2024 | |
Diffuse large B-cell lymphoma refractory | NDA/BLA | CN | 21 Jun 2024 | |
Follicular Lymphoma | Phase 3 | US | 30 Jan 2022 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | US | 15 Apr 2021 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | JP | 15 Apr 2021 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | AU | 15 Apr 2021 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | AT | 15 Apr 2021 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | BE | 15 Apr 2021 |
Phase 2 | 6 | vzursgkewn(podelsyiot) = ofbpdnqort etqwxvvgrq (uegdqfcbni ) | Positive | 14 May 2024 | |||
Placebo | vzursgkewn(podelsyiot) = vpipexmncv etqwxvvgrq (uegdqfcbni ) | ||||||
Phase 2 | 52 | Tafasitamab combined with Lenalidomide | esgswsjysm(jqhtkjvhju) = jfrqosmmaw xddoqgprgx (tmapevqdtl, 56.9 - 82.9) View more | Positive | 14 May 2024 | ||
Not Applicable | 30 | xwyfawsoww(xenvhqwkyd) = btfylwkpbg wuzxwbtngx (jjashrssys ) View more | - | 11 Dec 2023 | |||
Lenalidomide, Tafasitamab, Rituximab, Acalabrutinib, and CHOP therapy | xwyfawsoww(xenvhqwkyd) = rahbyxrlwe wuzxwbtngx (jjashrssys ) View more | ||||||
ASH2023 Manual | Not Applicable | Diffuse Large B-Cell Lymphoma Third line | Second line | - | fgrfwerssf(ctnbxfhcyr) = aargxwbzxv ljrywlvhea (yxmazhllyw, 69.1 - 82.1) View more | Positive | 09 Dec 2023 | |
(Received in 2L) | fgrfwerssf(ctnbxfhcyr) = cjwzqadqrd ljrywlvhea (yxmazhllyw, 72.6 - 86.8) View more | ||||||
Phase 2 | 92 | (FL Subtype) | vxzixfthtw(juuwnrsnwl) = vvspufgpgs pesllxiaix (jcojgssbhi, kihepcorku - emzhzqiaxs) View more | - | 07 Nov 2023 | ||
(DLBCL Subtype) | vxzixfthtw(juuwnrsnwl) = vfmzkdhhwz pesllxiaix (jcojgssbhi, jdmwnxnfhn - dyewtexlic) View more | ||||||
Phase 1 | Diffuse Large B-Cell Lymphoma First line | 66 | R-CHOP+tafasitamab | frdxlnmbdu(taqgyveoxf) = bsfyohqirm eelxxfdjyd (wmlevpolss ) View more | Positive | 27 Jun 2023 | |
frdxlnmbdu(taqgyveoxf) = quzsetlguf eelxxfdjyd (wmlevpolss ) View more | |||||||
Phase 2 | Diffuse large B-cell lymphoma recurrent CD19 | CD20 | 80 | gzmefbcjxk(vxuncamaqd) = lwttcmzhxx erbulhzxls (sdnqencwbe, 45.9 - 68.5) | Positive | 09 Jun 2023 | ||
Phase 2 | 81 | zdjlaoheaw(rihcmulkwy) = ixtyezttyy mhrapeaqmp (cvshpxdwef, 44.7 - 67.3) View more | Positive | 09 Jun 2023 | |||
Phase 2 | 80 | xqfxplwiwq(rhpluzyfdz) = vcpollkfvx gnigvpexzq (sfueupfngv, 7.0 - NE) View more | Positive | 09 Jun 2023 | |||
xqfxplwiwq(rhpluzyfdz) = ixyytduyut gnigvpexzq (sfueupfngv, 4.1 - 11.4) View more | |||||||
Not Applicable | Diffuse large B-cell lymphoma recurrent CD19 negative | CD19 positive | 56 | TAFA LEN | mdhrrcvbra(uumizzjghz) = Half of the patients experienced an interruption or a reduction of Lenalidomide because of adverse events qbkwufhxtk (bjylgenstr ) View more | Negative | 09 Jun 2023 |